Every Market Has Its Gate. We Know How to Open It.

The UK and European markets are two of the most valuable pharmaceutical environments in the world. Post-Brexit, they are also two distinct regulatory journeys that must each be navigated on their own terms.

For international companies and dossier holders seeking entry, the intersection of language, regulatory friction, and localized commercial frameworks creates an immediate barrier. Conversely, for UK and European manufacturers looking outward, finding a partner with genuine, compliant international reach is equally challenging.

Lexigen bridges both sides of this corridor. We maintain established relationships with specialty pharmaceutical manufacturers across the UK and EU, securing direct access to high-quality products and dossiers for international commercialisation. Simultaneously, we provide inbound partners with deep expertise in MHRA and EMA pathways, market access frameworks, NHS and EU payer dynamics, and robust cross-border supply chain capabilities.

Greater China stands as the world's second-largest pharmaceutical market and one of the most sophisticated and complex to enter. Intricate regulatory timelines, stringent language requirements, the necessity of local agents, and a deeply relationship-based commercial culture mean that market entry without the right strategic alignment rarely succeeds.

Lexigen has built dedicated commercial pathways connecting Greater China with international pharmaceutical markets. We support organisations seeking trusted distribution and commercial partners in mainland China, while simultaneously providing Chinese healthcare enterprises with credible, compliant routes into the UK, European, and GCC markets. Furthermore, our established commercial relationships and supply presence in Hong Kong serve as an invaluable gateway for regional connectivity and cross-border pharmaceutical activity.